ELLA 30 MG
ULIPRISTAL ACETATE : 30 MG · DIN 02436329 · LABORATOIRE HRA PHARMA
Health Canada status: MARKETED
What is ELLA?
ELLA 30 MG contains ULIPRISTAL ACETATE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02436329, held by LABORATOIRE HRA PHARMA, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Sep-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ELLA used for?
Prevention of pregnancy when taken within 120 hours (5 days) of unprotected intercourse or a known or suspected contraceptive failure. Not for routine use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02436329 |
|---|---|
| Brand name | ELLA |
| Generic / active ingredient | ULIPRISTAL ACETATE : 30 MG |
| Manufacturer | LABORATOIRE HRA PHARMA |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AD02 ULIPRISTAL |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Sep-2015 |
| Original market date | 2015-09-01 00:00:00 |
How is it administered?
One 30 mg tablet taken orally as soon as possible within 120 hours (5 days) of unprotected intercourse. If vomiting occurs within 3 hours, take another tablet.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text beyond section 11 header; typically store at 15-30°C (refer to full monograph).
How is it supplied?
PVC-PE-PVDC-aluminum blister of 1 tablet in a carton.
Contraindications
Hypersensitivity to the drug or any ingredient; known or suspected pregnancy.
Warnings and precautions
Does not protect against STIs/HIV. Efficacy may be reduced in women with BMI > 30 kg/m2. May cause dizziness/blurred vision affecting driving. Not for routine use.
Who else supplies ULIPRISTAL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ULIPRISTAL appears in 8 registered pack listings across 5 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.